Study on Immunotherapy (Ipilimumab and Nivolumab) for Patients with Recurrent Glioma with High Mutation Levels

Program Overview

This study is testing whether the combination of two immunotherapy drugs, ipilimumab and nivolumab, can help treat glioma that has come back and has a high number of mutations. Glioma is a type of brain cancer, and tumors with many mutations might respond well to immunotherapy. These drugs work by helping the immune system attack cancer cells and may stop the tumor from growing or spreading. The study compares this treatment to the usual care, which includes surgery or chemotherapy.

Description

The main goal of this study is to find out if using ipilimumab and nivolumab together can increase the rate at which tumors shrink in patients with recurrent glioblastoma that has many mutations. Researchers will also look at how long patients live, how long they live without the cancer getting worse, and what side effects they experience.

Patients will receive the drugs through an IV every three weeks for four cycles, as long as the cancer does not progress or cause unacceptable side effects. After that, they will receive nivolumab every four weeks. MRI scans will be used to monitor the cancer throughout the study.

After finishing the treatment, patients whose cancer has not progressed will be checked every eight weeks until it does, and then every three months for up to three years. Patients whose cancer progresses after treatment will be followed every three months for up to three years.

Eligibility Criteria

Locations